Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.

Hope S Rugo,Gerardo A Umanzor,Francisco J Barrios,Rosa H Vasallo,Marco A Chivalan,Suyapa Bejarano,Julio R Ramírez,Luis Fein,Ruben D Kowalyszyn,E Douglas Kramer,Hui Wang, Min-Fun R Kwan,David L Cutler

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 5|浏览3

暂无评分

摘要

oPac + E increased the confirmed tumor response versus IVpac, with trends in PFS and OS. Neuropathy was less frequent and severe with oPac + E; neutropenic serious infections were increased. Elevated liver enzymes at baseline predispose oPac + E patients to early neutropenia and serious infections (funded by Athenex, Inc; ClinicalTrials.gov identifier: NCT02594371).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要